Clinical Trials
31 trialsNCT06171789 2026-06-01
PRO1107 in Patients With Advanced Solid Tumors
Genmab
Phase 1/2 Terminated
NCT04234113 2026-03-27
Study of Nanrilkefusp Alfa Alone and With Pembrolizumab in Adult Patients With Advanced/Metastatic Solid Tumors
Sotio Biotech Inc.
Phase 1 Terminated
NCT04260802 2026-01-12
A Study to Evaluate the Safety and Pharmacokinetics of OC-001 in Patients With Locally Advanced or Metastatic Cancers
Ocellaris Pharma, Inc.
Phase 1/2 Terminated
NCT06052852 2025-11-17
Study of BDC-3042 as Single Agent and in Combination With Cemiplimab in Patients With Advanced Malignancies
Bolt Biotherapeutics, Inc.
Phase 1 Terminated
NCT05252390 2025-11-06
NUV-868 as Monotherapy and in Combination With Olaparib or Enzalutamide in Adult Patients With Advanced Solid Tumors
Nuvation Bio Inc.
Phase 1 Terminated
NCT06299163 2025-07-23
NM32-2668 in Adult Patients With Selected Advanced Solid Tumors
Numab Therapeutics AG
Phase 1 Terminated
NCT05714553 2025-07-18
NUC-3373 in Combination With Other Agents in Patients With Advanced Solid Tumours
NuCana plc
Phase 1/2 Terminated
NCT02419495 2025-06-04
Phase IB Study to Evaluate the Safety of Selinexor (KPT-330) in Combination With Multiple Standard Chemotherapy or Immunotherapy Agents in Patients With Advanced Malignancies
M.D. Anderson Cancer Center
Phase 1 Terminated
NCT03829501 2025-04-02
A Phase 1/2, Open-label, Multi-center Study of the Safety and Efficacy of Alomfilimab (KY1044) as Single Agent and in Combination With Anti-PD-L1 (Atezolizumab) in Adult Patients With Selected Advanced Malignancies
Kymab Limited
Phase 1/2 Terminated
NCT04254107 2025-02-10
A Safety Study of SEA-TGT (SGN-TGT) in Advanced Cancer
Seagen Inc.
Phase 1 Terminated
NCT03549000 2024-12-13
A Phase I/Ib Study of NZV930 Alone and in Combination With PDR001 and /or NIR178 in Patients With Advanced Malignancies.
Novartis
Phase 1 Terminated
NCT03207867 2024-10-09
A Phase 2 Study of NIR178 in Combination With PDR001 in Patients With Solid Tumors and Non-Hodgkin Lymphoma
Novartis
Phase 2 Terminated
NCT02554812 2024-07-30
JAVELIN Medley
Pfizer
Phase 1/2 Terminated
NCT03621982 2024-06-13
Study of ADCT-301 in Patients With Selected Advanced Solid Tumors
ADC Therapeutics S.A.
Phase 1 Terminated
NCT04691375 2024-03-22
A Study of PY314 in Subjects With Advanced Solid Tumors
Ikena Oncology
Phase 1 Terminated
NCT03992131 2024-01-16
A Study to Evaluate Rucaparib in Combination With Other Anticancer Agents in Participants With a Solid Tumor (SEASTAR)
pharmaand GmbH
Phase 1/2 Terminated
NCT04244552 2023-12-29
A Phase 1b Trial of ATRC-101 in Adults With Advanced Solid Malignancies
Atreca, Inc.
Phase 1 Terminated
NCT04551885 2023-09-21
FT516 in Combination With Monoclonal Antibodies in Advanced Solid Tumors
Fate Therapeutics
Phase 1 Terminated
NCT05069935 2023-09-21
FT538 in Combination With Monoclonal Antibodies in Advanced Solid Tumors
Fate Therapeutics
Phase 1 Terminated
NCT04639245 2023-08-03
Genetically Engineered Cells (MAGE-A1-specific T Cell Receptor-transduced Autologous T-cells) and Atezolizumab for the Treatment of Metastatic Triple Negative Breast Cancer, Urothelial Cancer, or Non-small Cell Lung Cancer
Fred Hutchinson Cancer Center
Phase 1/2 Terminated
NCT03576131 2023-08-01
GEN1029 (HexaBody®-DR5/DR5) Safety Trial in Patients With Malignant Solid Tumors
Genmab
Phase 1/2 Terminated
NCT04424641 2023-07-25
A Study on the Safety of GEN1044 (DuoBody®-CD3x5T4) in Patients With Malignant Solid Tumors
Genmab
Phase 1/2 Terminated
NCT03435640 2023-03-08
REVEAL
Nektar Therapeutics
Phase 1/2 Terminated
NCT05219578 2022-12-09
RTX-224 Monotherapy in Patients With Solid Tumors
Rubius Therapeutics
Phase 1/2 Terminated
NCT04060342 2022-08-18
GB1275 Monotherapy and in Combination With an Anti-PD1 Antibody in Patients With Specified Advanced Solid Tumors or in Combination With Standard of Care in Patients With Metastatic Pancreatic Adenocarcinoma
Gossamer Bio Inc.
Phase 1 Terminated
NCT04434560 2022-07-26
Neoadjuvant Immunotherapy in Brain Metastases
Duke University
Phase 2 Terminated
NCT03875313 2022-02-17
Study of CB-839 (Telaglenastat) in Combination With Talazoparib in Patients With Solid Tumors
Calithera Biosciences, Inc
Phase 1/2 Terminated
NCT03277352 2021-07-22
INCAGN01876 in Combination With Immune Therapies in Subjects With Advanced or Metastatic Malignancies
Incyte Corporation
Phase 1/2 Terminated
NCT03343613 2020-06-09
A Study of LY3381916 Alone or in Combination With LY3300054 in Participants With Solid Tumors
Eli Lilly and Company
Phase 1 Terminated
NCT02576665 2020-02-07
A Study of Toca 511, a Retroviral Replicating Vector, Combined With Toca FC in Patients With Solid Tumors or Lymphoma (Toca 6)
Tocagen Inc.
Phase 1 Terminated
NCT02543645 2018-04-30
A Study of Varlilumab and Atezolizumab in Patients With Advanced Cancer
Celldex Therapeutics
Phase 1 Terminated